A Phase 1/1b Study of IAM1363, a selective and brain penetrant HER2 inhibitor in participants (pts) with advanced cancers harboring HER2 alterations

Publication

October 19, 2025

A Phase 1/1b Study of IAM1363, a selective and brain penetrant HER2 inhibitor in participants (pts) with advanced cancers harboring HER2 alterations

Related articles

September 21, 2026

AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery

Bayer and Iambic collaborate to advance drug discovery with AI

Iambic Named to CNBC Disruptor 50 for Second Consecutive Year

Let's work together

Leverage the Iambic discovery process for your program. Reach out to us at partnerships@iambic.ai.